Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REPLIGEN CORPRGEN · Entity 486 | Director | May 14, 2026 | May 18, 2026 |
| STANDARD BIOTOOLS INC.FLDM · Entity 6116 | Director | April 01, 2022 | April 04, 2022 |
| Twist Bioscience CorpTWST · Entity 3619 | Director | November 21, 2022 | November 23, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REPLIGEN CORP
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,436 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 995 · Balance 5,436 F1: Mr. Barthelemy was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.38 · Expires 2036-05-14 | Direct | 2,239 |
Reported balance
After 2026-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-14 · Grant · Acquired 2,239 · Balance 2,239 F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Barthelemy was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
STANDARD BIOTOOLS INC.
Report date April 01, 2022 · Filed April 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectThe Barthelemy 2001 Trust | 204,077 |
Reported balance
After 2022-04-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-04-01 · Exercise / conversion · Acquired 20,993 · Balance 204,077 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.74 · Expires 2030-06-23 | Direct | 0 |
Reported balance
After 2022-04-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-04-01 · Exercise / conversion · Disposed 20,993 · Balance 0 |
Twist Bioscience Corp
Report date November 21, 2022 · Filed November 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,021 |
Reported balance
After 2022-11-21 transaction · row 1
1 source rowRow 1 · 2022-11-21 · Exercise / conversion · Acquired 9,082 · Balance 23,021 |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.33 · Expires 2029-10-23 | Direct | 11,279 |
Reported balance
After 2022-11-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-21 · Exercise / conversion · Disposed 9,082 · Balance 11,279 F1: 1/3 of the shares subject to the option vest and become exercisable on the first anniversary of October 24, 2020, and 1/3rd of the shares subject to the option vest and become exercisable on each anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/3 of the shares subject to the option vest and become exercisable on the first anniversary of October 24, 2020, and 1/3rd of the shares subject to the option vest and become exercisable on each anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
908 Devices Inc.
Report date June 15, 2022 · Filed June 17, 2022
Section 16 reporting ended · disclosed 2022-06-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001SEC Table I · non-derivative | Direct | 15,379 |
Reported balance
After 2022-06-15 transaction · row 1
1 source rowRow 1 · 2022-06-15 · Exercise / conversion · Acquired 1,379 · Balance 15,379 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-06-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-06-15 · Exercise / conversion · Disposed 1,379 · Balance 0 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F3: The RSUs became fully vested on June 15, 2022, the day prior to the 2022 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date. |
| Common Stock, par value $0.001SEC Table I · non-derivative | IndirectSee Footnote | 13,541 |
Reported balance
Holding disclosure · report date 2022-06-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 13,541 F2: These securities are owned directly by The Barthelemy 2001 Trust. The reporting person and his spouse are trustees of The Barthelemy 2001 Trust and have joint voting and dispositive control with respect to all securities held by The Barthelemy 2001 Trust and may be deemed to be the beneficial owner of the securities held by The Barthelemy 2001 Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested.
F2: These securities are owned directly by The Barthelemy 2001 Trust. The reporting person and his spouse are trustees of The Barthelemy 2001 Trust and have joint voting and dispositive control with respect to all securities held by The Barthelemy 2001 Trust and may be deemed to be the beneficial owner of the securities held by The Barthelemy 2001 Trust.
F3: The RSUs became fully vested on June 15, 2022, the day prior to the 2022 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 18, 2026 20:05 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 2,239 | $0.00 Strike: $103.38 | $0.00 |
DisclosureSEC source: 0001193125-26-228883 · ownership.xml · derivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,239 Underlying: Common Stock · 2,239 shares Expires 2036-05-14 F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 995 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-228883 · ownership.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,436 F1 · shares: Mr. Barthelemy was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 15, 2025 Filed May 21, 2025 19:00 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,800 | $0.00 Strike: $123.26 | $0.00 |
DisclosureSEC source: 0000950170-25-075705 · ownership.xml · derivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,800 Underlying: Common Stock · 1,800 shares Expires 2035-05-15 F2 · derivative.exercise_date: Award vests in full on the earlier of May 15, 2026, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 15, 2025 Filed May 21, 2025 19:00 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 973 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-075705 · ownership.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,441 F1 · shares: Mr. Barthelemy was awarded 973 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 15, 2026, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 21:42 UTC | REPLIGEN CORP RGEN · Entity 486 | PurchaseCommon Stock | 1,200 | $125.45 | $150,540.00 |
DisclosureSEC source: 0000950170-24-073840 · ownership.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,668 Read SEC document |
| May 16, 2024 Filed May 20, 2024 22:50 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,376 | $0.00 Strike: $171.03 | $0.00 |
DisclosureSEC source: 0000950170-24-062600 · ownership.xml · derivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,376 Underlying: Common Stock · 1,376 shares Expires 2034-05-16 F2 · derivative.exercise_date: Award vests in full on the earlier of May 16, 2025, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 16, 2024 Filed May 20, 2024 22:50 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 701 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062600 · ownership.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,468 F1 · shares: Mr. Barthelemy was awarded 701 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 16, 2025, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 18, 2023 Filed May 23, 2023 01:21 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,487 | $0.00 Strike: $156.63 | $0.00 |
DisclosureSEC source: 0000899243-23-013668 · doc4.xml · derivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,487 Underlying: Common Stock · 1,487 shares Expires 2033-05-18 F2 · derivative.exercise_date: Award vests in full on the earlier of May 18, 2024, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 18, 2023 Filed May 23, 2023 01:21 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 686 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-013668 · doc4.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,767 F1 · shares: Mr. Barthelemy was awarded 686 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 18, 2024, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| November 21, 2022 Filed Nov 23, 2022 16:16 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 9,082 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-22-014161 · marketforms-57658.xml · derivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,279 Underlying: Common Stock · 9,082 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/3 of the shares subject to the option vest and become exercisable on the first anniversary of October 24, 2020, and 1/3rd of the shares subject to the option vest and become exercisable on each anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| November 21, 2022 Filed Nov 23, 2022 16:16 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 9,082 | $23.33 | $211,883.06 |
DisclosureSEC source: 0001214659-22-014161 · marketforms-57658.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 16:14 UTC | 908 Devices Inc. MASS · Entity 5564 | Exercise / conversionRestricted Stock Unit · Derivative | 1,379 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-005191 · primarydocument.xml · derivative · entry 3 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 1,379 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F3 · derivative.exercise_date: The RSUs became fully vested on June 15, 2022, the day prior to the 2022 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date. F3 · derivative.expiration_date: The RSUs became fully vested on June 15, 2022, the day prior to the 2022 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 16:14 UTC | 908 Devices Inc. MASS · Entity 5564 | Exercise / conversionCommon Stock, par value $0.001 | 1,379 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-005191 · primarydocument.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. Read SEC document |
| May 26, 2022 Filed Jun 1, 2022 00:20 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,298 | $0.00 Strike: $159.17 | $0.00 |
DisclosureSEC source: 0000899243-22-020279 · doc4.xml · derivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,298 Underlying: Common Stock · 1,298 shares Expires 2032-05-26 F2 · derivative.exercise_date: Award vests in full on the earlier of May 26, 2023, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 26, 2022 Filed Jun 1, 2022 00:20 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 534 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020279 · doc4.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,081 F1 · shares: Mr. Barthelemy was awarded 534 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 26, 2023, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 11, 2022 Filed May 13, 2022 16:36 UTC | Twist Bioscience Corp TWST · Entity 3619 | PurchaseCommon Stock | 8,550 | $29.25 | $250,096.05 |
DisclosureSEC source: 0001214659-22-006826 · marketforms-56165.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,939 Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:16 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,993 | $3.74 Strike: $3.74 | $78,513.82 |
DisclosureSEC source: 0001162194-22-000027 · wf-form4_164910337858688.xml · derivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,993 shares Expires 2030-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:16 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionCommon Stock | 20,993 | $3.74 | $78,513.82 |
DisclosureSEC source: 0001162194-22-000027 · wf-form4_164910337858688.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Barthelemy 2001 Trust Disclosed balance after: 204,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2022 Filed Apr 2, 2022 00:31 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $3.43 Strike: $3.43 | $17,150.00 |
DisclosureSEC source: 0001162194-22-000025 · wf-form4_164885945022114.xml · derivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2027-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2022 Filed Apr 2, 2022 00:31 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionCommon Stock | 5,000 | $3.43 | $17,150.00 |
DisclosureSEC source: 0001162194-22-000025 · wf-form4_164885945022114.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Barthelemy 2001 Trust Disclosed balance after: 183,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 17:00 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 3,491 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-002210 · marketforms-55357.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,389 F1 · shares: 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 21:07 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,285 | $0.00 Strike: $128.18 | $0.00 |
DisclosureSEC source: 0000899243-21-042393 · doc4.xml · derivative · entry 4 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,285 shares Expires 2030-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 21:07 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 360 | $288.19 | $103,748.40 |
DisclosureSEC source: 0000899243-21-042393 · doc4.xml · nonDerivative · entry 3 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,547 Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 21:07 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,285 | $288.20 | $370,337.00 |
DisclosureSEC source: 0000899243-21-042393 · doc4.xml · nonDerivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,907 F1 · price: $288.20 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $288.20 to $288.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 21:07 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 1,285 | $128.18 | $164,711.30 |
DisclosureSEC source: 0000899243-21-042393 · doc4.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 21:49 UTC | 908 Devices Inc. MASS · Entity 5564 | Exercise / conversionStock Option (option to buy) · Derivative | 4,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001104659-21-085908 · tm2120792-2_4seq1.xml · derivative · entry 7 BARTHELEMY NICOLAS · CIK 0001283576 · Director · VP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,167 Underlying: Common Stock,par value $0.001 · 46,167 shares Expires 2028-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following March 20, 2018, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 21:49 UTC | 908 Devices Inc. MASS · Entity 5564 | SaleCommon Stock, par value $0.001 | 4,000 | $40.00 | $160,000.00 |
DisclosureSEC source: 0001104659-21-085908 · tm2120792-2_4seq1.xml · nonDerivative · entry 5 BARTHELEMY NICOLAS · CIK 0001283576 · Director · VP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Represents sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 21:49 UTC | 908 Devices Inc. MASS · Entity 5564 | Exercise / conversionCommon Stock, par value $0.001 | 4,000 | $1.58 | $6,320.00 |
DisclosureSEC source: 0001104659-21-085908 · tm2120792-2_4seq1.xml · nonDerivative · entry 4 BARTHELEMY NICOLAS · CIK 0001283576 · Director · VP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 21:49 UTC | 908 Devices Inc. MASS · Entity 5564 | Exercise / conversionStock Option (option to buy) · Derivative | 3,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001104659-21-085908 · tm2120792-2_4seq1.xml · derivative · entry 6 BARTHELEMY NICOLAS · CIK 0001283576 · Director · VP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,167 Underlying: Common Stock,par value $0.001 · 49,167 shares Expires 2028-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following March 20, 2018, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 21:49 UTC | 908 Devices Inc. MASS · Entity 5564 | SaleCommon Stock, par value $0.001 | 3,000 | $39.53 | $118,590.00 |
DisclosureSEC source: 0001104659-21-085908 · tm2120792-2_4seq1.xml · nonDerivative · entry 3 BARTHELEMY NICOLAS · CIK 0001283576 · Director · VP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Represents sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 21:49 UTC | 908 Devices Inc. MASS · Entity 5564 | Exercise / conversionCommon Stock, par value $0.001 | 3,000 | $1.58 | $4,740.00 |
DisclosureSEC source: 0001104659-21-085908 · tm2120792-2_4seq1.xml · nonDerivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director · VP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 21:49 UTC | 908 Devices Inc. MASS · Entity 5564 | SaleCommon Stock, par value $0.001 | 6,000 | $39.63 | $237,780.00 |
DisclosureSEC source: 0001104659-21-085908 · tm2120792-2_4seq1.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director · VP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 13,541 F1 · kind: Represents sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.02 to $39.91, inclusive. The reporting person undertakes to provide to 908 Devices Inc., any security holder of 908 Devices Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · ownership.nature: These securities are owned directly by The Barthelemy 2001 Trust. The reporting person and his spouse are trustees of The Barthelemy 2001 Trust and have joint voting and dispositive control with respect to all securities held by The Barthelemy 2001 Trust and may be deemed to be the beneficial owner of the securities held by The Barthelemy 2001 Trust. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 08:06 UTC | 908 Devices Inc. MASS · Entity 5564 | GrantRestricted Stock Unit · Derivative | 1,379 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-083128 · tm2120211-3_4seq1.xml · derivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,379 Underlying: Common Stock, par value $0.001 · 1,379 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F3 · derivative.exercise_date: The RSUs become fully vested on June 17, 2022 or the 2022 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. F3 · derivative.expiration_date: The RSUs become fully vested on June 17, 2022 or the 2022 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 08:06 UTC | 908 Devices Inc. MASS · Entity 5564 | GrantStock Option (option to buy) · Derivative | 2,455 | $0.00 Strike: $41.70 | $0.00 |
DisclosureSEC source: 0001104659-21-083128 · tm2120211-3_4seq1.xml · derivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,455 Underlying: Common Stock, par value $0.001 · 2,455 shares Expires 2031-06-17 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 17, 2021, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| May 25, 2021 Filed May 27, 2021 21:33 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 15,402 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0001162194-21-000063 · wf-form4_162215116016959.xml · derivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,402 Underlying: Common Stock · 15,402 shares Expires 2031-05-25 F2 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly increments beginning on June 25, 2021. Read SEC document |
| May 25, 2021 Filed May 27, 2021 21:33 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantCommon Stock | 10,342 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-21-000063 · wf-form4_162215116016959.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Barthelemy 2001 Trust Disclosed balance after: 178,084 F1 · shares: The Restricted Stock Units vest in full on the earlier to occur of May 25, 2022 and one day prior to the date of the Company's next annual meeting of stockholders. Read SEC document |
| May 13, 2021 Filed May 18, 2021 01:56 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,151 | $0.00 Strike: $169.65 | $0.00 |
DisclosureSEC source: 0000899243-21-019710 · doc4.xml · derivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151 Underlying: Common Stock · 1,151 shares Expires 2031-05-13 F2 · derivative.exercise_date: Award vests in full on the earlier of May 13, 2022, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 13, 2021 Filed May 18, 2021 01:56 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 457 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-019710 · doc4.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,907 F1 · shares: Mr. Barthelemy was awarded 457 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 13, 2022, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 21:09 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-21-000016 · wf-form4_161670656001565.xml · derivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock. F2 · derivative.exercise_date: On March 23, 2017, the Reporting Person was granted 10,000 Restricted Stock Units vesting as to 25% of the total number of shares underlying the Restricted Stock Units on each anniversary date after the date of grant on the same day of the month as the date of grant, subject to continued service as a director. F2 · derivative.expiration_date: On March 23, 2017, the Reporting Person was granted 10,000 Restricted Stock Units vesting as to 25% of the total number of shares underlying the Restricted Stock Units on each anniversary date after the date of grant on the same day of the month as the date of grant, subject to continued service as a director. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 21:09 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-21-000016 · wf-form4_161670656001565.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Barthelemy 2001 Trust Disclosed balance after: 167,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 16:39 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-21-001555 · marketforms-51451.xml · derivative · entry 3 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,573 Underlying: Common Stock · 5,000 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/3rd of the shares subject to the option vested and became exercisable on October 24, 2020 and each annual anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 16:39 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,000 | $177.61 | $888,034.50 |
DisclosureSEC source: 0001214659-21-001555 · marketforms-51451.xml · nonDerivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,898 F1 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $177.22 to $178.07 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 16:39 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 5,000 | $23.33 | $116,650.00 |
DisclosureSEC source: 0001214659-21-001555 · marketforms-51451.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantDirector Stock Option (right to buy) · Derivative | 973 | $0.00 Strike: $189.96 | $0.00 |
DisclosureSEC source: 0001214659-21-001428 · marketforms-51430.xml · derivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 973 Underlying: Common Stock · 973 shares Expires 2031-02-02 F2 · derivative.exercise_date: 100% of the shares subject to the option will vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 486 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-001428 · marketforms-51430.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,898 F1 · shares: Represents a restricted stock unit award (the "RSU Award") of which 100% vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 22, 2020 Filed Dec 22, 2020 20:20 UTC | 908 Devices Inc. MASS · Entity 5564 | ConversionSeries E Preferred Stock · Derivative | 19,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-138748 · tm2039218d3_4.xml · derivative · entry 3 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 19,541 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series E Preferred Stock (the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · derivative.exercise_date: Each share of Series E Preferred Stock (the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · derivative.expiration_date: Each share of Series E Preferred Stock (the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F2 · ownership.nature: These securities are owned directly by The Barthelemy 2001 Trust. The reporting person and his spouse are trustees of The Barthelemy 2001 Trust and have joint voting and dispositive control with respect to all securities held by The Barthelemy 2001 Trust and may be deemed to be the beneficial owner of the securities held by The Barthelemy 2001 Trust. Read SEC document |
| December 22, 2020 Filed Dec 22, 2020 20:20 UTC | 908 Devices Inc. MASS · Entity 5564 | PurchaseCommon Stock, par value $0.001 | 14,000 | $20.00 | $280,000.00 |
DisclosureSEC source: 0001104659-20-138748 · tm2039218d3_4.xml · nonDerivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Read SEC document |
| December 22, 2020 Filed Dec 22, 2020 20:20 UTC | 908 Devices Inc. MASS · Entity 5564 | ConversionCommon Stock, par value $0.001 | 19,541 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-138748 · tm2039218d3_4.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 19,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series E Preferred Stock (the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F2 · ownership.nature: These securities are owned directly by The Barthelemy 2001 Trust. The reporting person and his spouse are trustees of The Barthelemy 2001 Trust and have joint voting and dispositive control with respect to all securities held by The Barthelemy 2001 Trust and may be deemed to be the beneficial owner of the securities held by The Barthelemy 2001 Trust. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 19:00 UTC | 908 Devices Inc. MASS · Entity 5564 | GrantStock Option (option to buy) · Derivative | 14,410 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001104659-20-138178 · tm2039029-1_4seq1.xml · derivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,410 Underlying: Common Stock, par value $0.001 · 14,410 shares Expires not disclosed F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following December 17, 2020, subject to the reporting person's continued service through the applicable vesting date. F1 · derivative.expiration_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following December 17, 2020, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| November 09, 2020 Filed Nov 11, 2020 02:18 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,214 | $195.51 | $237,349.14 |
DisclosureSEC source: 0000899243-20-030760 · doc4.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,450 F1 · price: $195.51 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $195.09 to $195.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.